Skip to main content
Journal cover image

INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY)

Conferences
Desjardins, A; Conlon, K; Gunning, H; Davies, R; Komisarow, J; Cavaliere, R; Zamoryakhin, D
Published in: NEURO-ONCOLOGY
November 2022

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 2022

Volume

24

Start / End Page

79 / 79

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Desjardins, A., Conlon, K., Gunning, H., Davies, R., Komisarow, J., Cavaliere, R., & Zamoryakhin, D. (2022). INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY). In NEURO-ONCOLOGY (Vol. 24, pp. 79–79).
Desjardins, Annick, Kelly Conlon, Hannah Gunning, Rhian Davies, Jordan Komisarow, Robert Cavaliere, and Dmitry Zamoryakhin. “INITIATION OF A PHASE 1 DOSE-ESCALATING STUDY OF WEEKLY DIRECT-TO-BRAIN ADMINISTRATION OF SOLUBILISED FORMULATION OF PANOBINOSTAT (MTX110) IN PATIENTS WITH RECURRENT GLIOBLASTOMA (MAGIC-G1 STUDY).” In NEURO-ONCOLOGY, 24:79–79, 2022.
Journal cover image

Published In

NEURO-ONCOLOGY

EISSN

1523-5866

ISSN

1522-8517

Publication Date

November 2022

Volume

24

Start / End Page

79 / 79

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis